Pharma's presidential picks

In an industry known for backing Republicans, Sen. Barack Obama has emerged as a surprising pharma favorite in the US presidential election. In April, Obama won a mock election at the annual DTC national meeting, a drug advertising conference, with a 53% to 46% victory over Sen. John McCain. Drug companies have also put the money where their mouth is: Pharma has donated three times more to the Obama campaign than to McCain's. According to a linkurl:Bloomberg News report;http://www.bloomber

Written byMegan Scudellari
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share
In an industry known for backing Republicans, Sen. Barack Obama has emerged as a surprising pharma favorite in the US presidential election. In April, Obama won a mock election at the annual DTC national meeting, a drug advertising conference, with a 53% to 46% victory over Sen. John McCain. Drug companies have also put the money where their mouth is: Pharma has donated three times more to the Obama campaign than to McCain's. According to a linkurl:Bloomberg News report;http://www.bloomberg.com/apps/news?pid=newsarchive&sid=aRCVqfSQ43Eo citing data from the Center for Responsive Politics (CRP), pharma execs and employees have donated $450,094 to Obama, compared to $132,575 to McCain. CRP's Web site also lists linkurl:figures;http://www.opensecrets.org/industries/recips.php?cycle=2008&ind=H04 for donations that include pharmaceutical companies and makers of medical devices and other health-related products: Obama is ranked as the top recipient of donations in that category with $848,001, while McCain is in fourth place (behind Clinton and Romney) with $347,375. It's a clear contrast to the 2004 election, in which drug industry donations to George W. Bush almost doubled those to John Kerry. This year's top pharma donations come from Pfizer, Amgen, and Johnson & Johnson, according to CRP's website. Republican lobbyist John Feehery told Bloomberg the lack of industry funding helps McCain, solidifying his reputation as someone who fights special interests. "He goes after these companies and they don't like it." In a linkurl:recent CNBC article,;http://www.cnbc.com/id/26220788 analysts at Stratega Research Partners forecast that both Obama and McCain would be bad for big pharma because of their support for government regulation of Medicare drugs and reimportation, buy-back of American made drugs at abroad prices. Both candidates are expected to be positive forces for generics as the two men endorse moving drugs to the market faster, the article notes. For more on science in the upcoming election, stay tuned for our September issue and accompanying online content, for a look at key thought leaders poised to influence science policy during the next administration, and featuring a round-up of how the candidates stack up on science-related issues. August 19: This blog has been updated from a previous version
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies